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ABSTRACT
Alsabi Qamar. M.S.B.M.E., Department of Biomedical, Industrial, and Human Factor
Engineering, Wright State University, 2019. Characterizing Basal-Like Triple Negative
Breast Cancer using Gene Expression Analysis: A Data Mining Approach.

Triple-negative breast cancer (TNBC) is characterized by the absence of expression of the
estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2
(HER2). Therefore, TNBC is unresponsive to targeted hormonal therapies, which limits
treatment options to nonselective chemotherapeutic agents. Basal-like breast cancers
(BLBCs) represent a subset of about 70% of TNBCs, more frequently affecting younger
patients, being more prevalent in African-American women and significantly more
aggressive than tumors of other molecular subtypes, with high rates of proliferation and
extremely poor clinical outcomes. Proper classification of BLBCs using current
pathological tools has been a major challenge. Although TNBCs have many BLBC
characteristics, the relationship between clinically defined TNBC and the gene expression
profile of BLBC is not fully examined. The purpose of this study is to assemble publiclyavailable TNBC gene expression datasets generated by Affymetrix gene chips and define
a set of genes, or gene signature, that can classify TNBC samples between BLBC and NonBLBC subtypes. We compiled over 3,500 breast cancer gene expression profiles from
several individual publicly available datasets and extracted Affymetrix gene expression
data for 580 TNBC cases. Several popular data mining methods along with dimensionality
reduction and feature selection techniques were applied to the resultant dataset to build

iii

predictive models to understand molecular characteristics and mechanisms associated
with BLBCs and to classify them more accurately according to important features extracted
through microarray data analysis of BLBC and Non-BLBC cases. Our result can lead to
proper identification and diagnosis of BLBCs, which can potentially direct clinical
implications by dictating the most effective therapy.
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Introduction
Triple-negative breast cancer (TNBC) constitutes approximately 20%-25% of all
breast cancer cases with poor prognosis.1 TNBC is defined as the lack of specific breastcancer-associated receptors, mainly progesterone (PR), estrogen (ER), and human
epidermal growth factor (HER2). As a result, due to the lack of targets TNBC is
unresponsive to targeted hormonal therapies, which limits treatment options to
nonselective chemotherapeutic agents.2
Recent technological advances allow for high throughput profiling of biological systems
at the molecular level in a cost-efficient manner. The relatively low cost of data generation
is leading us to the "Big Data Era". Today big data can be created out of small data and the
combination of datasets from various sources is a major aspect of “big data”. The
availability of such large datasets provides unprecedented opportunities for data mining,
deep learning, and integrative analysis over various layers of data which set the goal to link
all the molecular information and translate it back into meaningful information in precision
medicine, systems biology, molecular physiology or pathophysiology.
Translational modeling is not new to cancer research. Predictive modeling has been applied
in clinical domains and into a wide variety of problems in breast cancer such as

1

KR Bauer. Descriptive analysis of estrogen receptor (ER)- negative, progesterone receptor (PR)-negative.
And HER2-negative invasive breast cancer. The so-called triple-negative phonotype. (population-based
study from the California cancer Registry). 1721-1728
2
Ibid
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diagnosis3,survivability4, prognosis5, susceptibility6 and recurrence7. However, the extent
to which microarray data can improve the diagnosis of BLBC cancer has not been fully
examined.
The purpose of this analysis is to assemble publicly-available TNBC gene
expression datasets generated on Affymetrix gene chips and define a set of genes, or gene
signature, that can classify TNBC between the basal-like breast cancer (BLBC) and Nonbasal-like breast cancer (Non-BLBC) subtypes. A proper diagnosis of BLBC will have
clinical implications by dictating the most effective therapy.
The approach that used to characterize basal-like triple negative breast cancer is
data mining approach using supervised analysis (i.e., classification). Eight data mining
techniques were used to classify basal-like triple negative breast cancer include Neural
Network, Decision tree, Logistic Regression, Support Vector Machine, Least Angle
Regression, Gradient, Random Forrest, and Bayesian Classifier.

3

Akay, M. F. (2009). Support vector machines combined with feature selection for breast cancer
diagnosis. Expert Systems with Applications, 36(2), 3240-3247
4
D Delen., G Walker., & A Kadam. Predicting breast cancer survivability: a comparison of three data
mining methods. Artificial intelligence in medicine, 34(2), 113-127 (2005).
5
Chen, A. H., & Yang, C. (2012). The improvement of breast cancer prognosis accuracy from integrated
gene expression and clinical data. Expert Systems with Applications, 39(5), 4785-4795.
6
Ayer, T., Alagoz, O., Chhatwal, J., Shavlik, J. W., Kahn Jr, C. E., & Burnside, E. S. (2010). Breast cancer risk
estimation with artificial neural networks revisited: discrimination and calibration. Cancer, 116(14), 33103321.
7
Kim, W., Kim, K. S., Lee, J. E., Noh, D.-Y., Kim, S.-W., Jung, Y. S., . . . Park, R. W. (2012). Development of
novel breast cancer recurrence prediction model using support vector machine. Journal of breast cancer,
15(2), 230-238.
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Background
Breast Cancer (BC)
Environmental and genetic factors are the main causes of Breast Cancer (BC), due to the
accumulation of mutations in essential genes.8 In developed countries, BC is the most
common cancer in women, being the cause of death in approximately 20% of females
diagnosed.9 In the case of African-American women under the age of 50 years of age 39%
of the diagnosed BC cases are of the TNBC type, while they only represent 16% in
Caucasian women.10 Based on global gene expression analyses, four molecular subtypes
of BC have been identified, mainly, luminal A, luminal B, HER2-enriched and basal-like.
These subtypes have shown to be significantly different in terms of their baseline
prognosis, age at diagnosis, risk factors and response to therapies. Among these types,
basal-like breast cancer is of great interest to investigators and clinicians due to its poor
prognosis, high frequency, limited targeted therapies.11

Triple Negative Breast Cancer (TNBC)
TNBC is defined as a type of BC which shows the absence of the three common BC
biomarkers, PR, ER, and HER2.12 TNBC tends to be more aggressive compared to other
BC types. In addition, the chance of early recurrence is high, due to the absence of the
ER.13

8

Nathanson K.N, Wooster R, Weber B.L. Breast cancer genetics: What we know and what we need. 552556
9
F Macdonald, Ford CHJ, AG Casson. Breast cancer. In ‘Molecular Biology of Cancer’.139-63
10
LA Carey, CM Perou and CA Livasy. Race, breast cancer subtypes, and survival in the Carolina breast
cancer study. 2492-502
11
Prat Aleix, A Barbara, C Maggie, A Carey, C Lisa and P Charles. Molecular Characterization of Basal-Like
and None-Basal-Like Triple-negative Breast Cancer. 123-133
12
KR Bauer. (2007). 1721-1728
13
Ibid
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The absence of the BC-specific targets ER, PR, and HER2, limits the treatment options for
TNBC. These include hormone therapies, anti-HER2 targeted therapies, endocrine
(tamoxifen, aromatase inhibitor inhibitors) therapy, and trastuzumab (anti-HER2). TNBC
cases only achieve 19% clinical-complete-response to chemotherapy.14 This leaves as the
only treatment option available for TNBC, cytotoxic chemotherapy.15
Although TNBC has many BLBC characteristics, the relationship based on the gene
expression is not completely clear, where not all TNBC cases fall into the BLBC subtype.16

Basal-like Breast Cancer (BLBC)
BLBC represents approximately 15-20% of breast cancer cases,17 and is defined as being
ER negative, PR negative, cytokeratin 5/6 positive and/or HER2 positive.18 It mainly
occurs at an early age, showing an aggressive clinical outcome, presence of distant
metastases, especially within the first five years after the diagnosis, showing poor
prognosis, and a high mortality rate.

BLBC subtype of TNBC
Based on the protein profile, 53-84% of TNBC cases are diagnosed as BLBC.19 Another
study reported that 6 of 31 (19.4%) triple- negative breast tumors were classified as Non-

14

J Choi, WH Jung and JS Koo. Clinicopathologic features of molecular subtypes of triple negative breast
cancer based immohistochemical markers. 1481-93
15
C liedtke, C Mazouni, KR Hess, F Tordai, JA Mejia, WF symmans, AM Gonzalez-Angulo, B Hennessy and
M Green. Response to neoadjuvant therepy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol. 1275-1281
16
P Boyle. Triple-negative breast cancer: epidemiological considerations
17
Badowsha-Kozakiewicz and Budzik: Immunohistochemical charactristics of basal-like breast cancer.436443
18
Ibid
19
Y Liu, T Xin and QY Jiang. CD147, MMP9 expression and clinical significance of basal-like breast cancer.
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BLBC, while 15 out of 207 (6.3%) non-triple-negative tumors showed basal cytokeratin
biomarkers.20 A previous investigation showed that 69.7% of TNBC were classified as
BLBC.21 Until now, there is no accepted definition to classify BLBC. To improve the
criteria for defining BLBC, some studies included microarray-based expression profiling
data, and panels of immunohistochemical surrogates, which yielded a definition that
included cancer tissue (1) with the absence of ER, PR, and HER2 expression (i.e., triplenegative); (2) expressing one or more high-molecular-weight/basal cytokeratin (i.e.,
CK5/6, CK14, or CK17), which are usually expressed in the basal epithelial layer of skin
and airways, but are also expressed in some breast carcinomas; (3) absence of ER and
HER2 expression in conjunction with CK5/6 and or epidermal growth factor EGFR; (4)
absence of ER, PR, and HER2 expression in conjunction with CK5/6 and/or EGFR.22

Diagnostic Difficulties
Unlike other subtypes of BC, the BLBC subtype seems not to correlate with the size of the
primary tumor and the presence of regional lymph node metastases.23 However, there are
a variety of immunohistochemical markers that can be used to identify BLBC, such as
cytokeratins (CK5/6, CK14 or CK17), EGFR, smooth muscle actin (SMA), p63, pcadherin, ki-67, p53 or c-kit antigen with concomitant lack of ER, PR, HER2 and “luminal”
cytokertins (CK8, CK18, CK19) expression.24 BLBC shows higher genome instability
compared to other BC subtypes. Therefore, there is no particular set of markers that

20

DS Tan, C Marchio, RL Jones. Triple negative breast cancer: molecular profiling and progistic impact in
adjuvant anthracycline-treated patients. 27-44
21
Rody.(2011). A clinically relevant gene signature in triple negative and basal-like breast cancer.
22
MC Cheang. Basal-like breast cancer defined by five biomarkers has superior value than triple-negative
phenotype. 1368-1376
23
Badowsha-Kozakiewicz and Budzik (2016).436-443
24
Ibid
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explicitly define BLBC.25 However, a more detailed classification of TNBC tumors needs
to be established because of the variability shown within this type based on molecular
studies26. Moreover, to define better prognostic biomarkers and therapeutic alternatives,
further investigations are needed to better classify TNBC, BLBC, and Non-BLBC tumors.

Biomarkers in TNBC and BLBC
A biomarker is a biological molecule that serves as a sign for normal biological processes
or conditions or signals the presence of an abnormal process, condition, and thus, the
presence of a biological defect, risk to a particular ailment, or an actual disease.
Researchers have explored biomarkers for selected types of cancer to aid in prevention or
risk assessment, diagnostic, and treatment or management27. Nonetheless, the existing
body of literature remains unorganized when it comes to biomarkers for more specific types
of cancer, such as in the case of TNBC as BLBC, TNBC as Non-BLBC, or Non-TNBC as
BLBC.
Two of the earliest identified biomarkers for general breast cancer are BRCA1 and
BRCA2, which are related tumor suppressor genes responsible for repairing DNA or
destroying cells if DNA damage is irreparable. Damage in either of these two genes, due
to specific heritable mutations, increases the risk of cancer in breast tissue, as well as in
ovarian and blood tissue due to the loss DNA repair capacity28 Although, both BRCA1 and
BRCA2 are important biomarkers for susceptibility to breast and other types of cancer,

25

Badowsha-Kozakiewicz and Budzik.(2016).436-443.
Ibid
27
Verma, Mukesh, and Upender Manne. “Genetic and Epigenetic Biomarkers in Cancer Diagnosis and
Identifying High Risk Populations.” Critical Reviews in Oncology/Hematology 60, no. 1 (October 2006): 9–
18.
28
Friedenson, Bernard. “The BRCA1/2 Pathway Prevents Hematologic Cancers in Addition to Breast and
Ovarian Cancers.” BMC Cancer 7, no. 1 (August 6, 2007). doi:10.1186/1471-2407-7-152.
26
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their capacity in defining susceptibility and presence of TNBC and BLBC, has been very
limited.
Several review studies have identified other alternative biomarkers. For instance, one
study29 did a comprehensive review of PubMed and conference databases to evaluate the
literature concerning TNBC biomarkers. The study listed the following biomarkers:
epidermal growth factor receptor (EGFR), vascular endothelial growth factor, c-Myc, Ckit, basal cytokeratins, poly(ADP-ribose) polymerase-1, p53, tyrosinase kinases, m-TOR,
heat and shock proteins, and TOP-2A. The same study30 noted that the absence of estrogen
receptors or ER, progesterone receptors or PR, and HER-2/neu receptors are distinctive
biomarkers for BLBC and they represent 80% of TNBC cases. Other studies31 have
identified additional biomarkers for BLBC, including EGFR and cytokeratin CK 5/6,
which are keratin proteins that serve as essential components of intermediate filaments that
help cells resist mechanical stress.
It is also important to note the differential expression of other keratin proteins is also seen
in both TNBC and BLBC. For instance, the differential expression of CK7, CK8, CK18,
and CK19 was observed in more than 90 percent of all breast carcinomas. In addition, the
expression of CK5/6, CK14, and CK20 positively correlated with a high tumor grade.32
Another study33 that analyzed 11 TNBC tumors, identified the specific occurrence of

29

Yadav, Budhi S. “Biomarkers in Triple Negative Breast Cancer: A Review.” World Journal of Clinical
Oncology 6, no. 6 (2015): 252. https://doi.org/10.5306/wjco.v6.i6.252.
30
Ibid
31
Cheang, M. C.U., D. Voduc, C. Bajdik and S. Leung, 1368–76.
32
Shao, M.-M., Chan, S. K., Yu, and A. M. C. (2012). Keratin expression in breast cancers. Virchows Archiv,
461(3), 313–322.
33
Kuroda, Naoto, Masahiko Ohara, Kaori Inoue and Keiko Mizuno. “The Majority of Triple-Negative Breast
Cancer May Correspond to Basal-like Carcinoma, but Triple-Negative Breast Cancer Is Not Identical to
Basal-like Carcinoma.” Medical Molecular Morphology 42, no. 2 (June 2009): 128–31.
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keratins. For example, eight of the tumors were positive for basal markers, CK5 and CK17,
six of which also were also positive for CK14. The study concluded that the use of
combination immunohistochemistry, which included CK5, CK14, and CK17, could
contribute to the detection of basal-like carcinoma.
Overexpression of the protein-coding gene ID4, which is associated with the regulation of
many cellular processes during both prenatal development and tumorigenesis, and TP53,
which prevents cancer formation through tumor suppression and genome mutation
prevention, have been linked to BLBC. The high expression of Ki67 mRNA has also been
associated with the high proliferation of BLBC subtype.34 Note that this nuclear protein
has been suggested to play a necessary role in cellular proliferation, as well as in the
ribosomal RNA transcription.
Other biomarkers have been identified to indicate both prognosis and therapeutic response
to TNBC and BLBC. For example, secreted frizzled related protein 1 or SFRP1 has been
found to be a potential molecular marker for response to chemotherapy and potential
prognostic marker35 and an increased secretion of this protein has been associated with
higher expression in basal-like cancer cell lines. Thus, one study concluded that SFRP1 is
correlated with both an aggressive form of breast cancer and positive response to
neoadjuvant chemotherapy.36

34

Yadav, 252-263
Huelsewig, Carolin, Christof Bernemann and Christian Ruckert. “Abstract 920: Secreted Frizzled Related
Protein 1 (SFRP1) as Potential Regulator of Chemotherapy Response for Patients with Triple Negative
Breast Cancer (TNBC).” In Clinical Research (Excluding Clinical Trials). American Association for Cancer
Research, 2014.
36
Bernemann, Christof, Carolin Hülsewig and Christian Ruckert et al. “Influence of Secreted Frizzled
Receptor Protein 1 (SFRP1) on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Does Not Rely
on WNT Signaling.” Molecular Cancer 13, no. 1 (2014): 174.
35
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Another notable example centers on the interplay between two genes that are both
indicative of cancer development and prognosis. For instance, one study37 revealed that
microRNA-26 appears to inhibit the metastasis of TNBC, by targeting transmembrane 4
L6 family member 1 or TM4SF1. Note that TM4SF1 expression in breast cancer tissues is
higher than that in adjacent normal breast tissues. Furthermore, the expression level of
TM4SF1 in MDA-MB-231 cells was associated with the metastatic tendency of TNBC.
Nonetheless, the overexpression of miR-206 in the same MDA-MB-231 cells appears to
down-regulate TM4SF1.
The interplay with forkhead box C1 or FOXC1 and chemokine receptor-4 or CXRC4, also
affect TNBC and BLBC prognosis and metastasis. Specifically, FOXC1 overexpression
boosts TNBC metastasis by activating the transcription of CXRC4. However, in a zebrafish
tumor model, either AMD3100 or siRNA in MDA-MB-231 cells can inhibit CXRC4 by
under-expressing FOXC1.38
Moreover, primary breast cancer tissues and its derived cell lines and, particularly, in
TNBC tissues and cell lines have up-regulated microRNA-761. The overexpression of
exogenous microRNA-761 augmented the TNBC cell proliferation, colony formation,
migration, and invasion in vivo. Essentially, microRNA-761 represses the expression of
TRIM29, thus inducing aggressive phenotypes in TNBC cells. On the other hand, the
overexpression of TRIM29 reversed the proliferative and invasive capacities of TNBC

37

Fan, Chunni, Ning Liu, Dan Zheng, Jianshi Du, and Keren Wang. “MicroRNA-206 Inhibits Metastasis of
Triple-Negative Breast Cancer by Targeting Transmembrane 4 L6 Family Member 1.” Cancer Management
and Research Volume 11 (July 2019): 6755–64.
38
Pan, Hongchao, Zhilan Peng, Jiediao Lin and Xiaosha Ren. “Forkhead Box C1 Boosts Triple-Negative
Breast Cancer Metastasis through Activating the Transcription of Chemokine Receptor-4.” Cancer Science
109, no. 12 (November 18, 2018): 3794–3804.
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cells39. Note that microRNA-761 is a non-coding RNA that affects the translation and
stability of mRNAs. TRIM29 or tripartite motif-containing protein 2 encodes a gene
belonging to the TRIM protein family and may act as a regulatory factor involved in
carcinogenesis and/or differentiation. However, a high level of another TRIM protein
known as TRIM28 with TNBC. The down-regulation and depletion of this protein reduced
the ability of TNBC cells to induce tumor growth when injected subcutaneously, thereby
resulting in a significant reduction of tumor growth.40
Another gene linked to the proliferation of cancerous mammary cells is actin-related
protein 2/3 complex or ARPC2. One study41 screened the Oncomine database and found
micro-profiling studies that linked the overexpression of ARPC2 proteins to cancerous cell
lines. Furthermore, they found a unique link between ARCP2 overexpression and invasion,
apoptosis, and proliferation of mammary carcinoma cells, including tumor size, lymph
node metastasis, tumor grade, poor prognosis and response to treatment. Another study42
showed that that the up-regulation of stearoyl-CoA desaturase 1 or SCD1 was associated
with shorter survival in breast cancer patients. A study43 of specific TNBC subtypes, noted
that SCD1 inhibition had been reported to reduce the proliferation and survival of cancer
cells, thereby suggesting a new targeted therapeutic approach.

39

Guo, Guang-Cheng, Jia-Xiang Wang, Ming-Li Han, Lian-Ping Zhang, and Lin Li. “microRNA-761 Induces
Aggressive Phenotypes in Triple-Negative Breast Cancer Cells by Repressing TRIM29 Expression.” Cellular
Oncology 40, no. 2 (January 4, 2017): 157–66.
40
Czerwińska, Patrycja, Parantu K. Shah and Katarzyna Tomczak et al. “TRIM28 Multi-Domain Protein
Regulates Cancer Stem Cell Population in Breast Tumor Development.” Oncotarget 8, no. 1, 10 Nov 2016.
41
Cheng, Zhongle, Wei Wei, Zhengshen Wu, Jing Wang, Xiaojuan Ding, Youjing Sheng, Yinli Han, and Qiang
Wu. “ARPC2 Promotes Breast Cancer Proliferation and Metastasis.” Oncology Reports, April 12, 2019.
42
Holder, Ashley M., Ana M. Gonzalez-Angulo and Huiqin Chen. “High Stearoyl-CoA Desaturase 1
Expression Is Associated with Shorter Survival in Breast Cancer Patients.” Breast Cancer Research and
Treatment 137, no. 1 (December 4, 2012): 319–27.
43
Hosokawa, Yuko, Noritaka Masaki and Shiro Takei. “Recurrent Triple-Negative Breast Cancer (TNBC)
Tissues Contain a Higher Amount of Phosphatidylcholine (32:1) than Non-Recurrent TNBC Tissues.”, no. 8
(August 23, 2017).
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The mRNA expressions of several S100 family of genes have been associated with
malignancies in human breast tissue. In the case of TNBC, an analysis44 using the KaplanMeier plotter database revealed that S100P expression is significantly associated with poor
survival in TNBC patients. The abundance of mRNA S100P is indicative of poor overall
survival of these patients. Another study45 involved silencing the pi subunit of the
GABA(A) receptor or GABRP in vitro. Results revealed a decreased GABRP tumorigenic
potential and migration to be concurrent with alterations in the cytoskeleton of basal-like
cell lines, by reducing cellular protrusions and expression of several cytokeratin proteins
related with BLBC, such as KRT5, KRT6B, KRT14, and KRT17.
The identification of genetic biomarkers for TNBC and BLBC should involve considering
the following three points. First, focus on genes that can determine the existence and earlystage development of TNBC and BLBC. Examples of these genes include the underexpressed BRCA1 and BRCA2 tumor suppressor genes, as well as the under-expressed
ER, PR, and HER2 receptors.46 47 Also, overexpressed keratin proteins EGPR, ID4, TP53,
and Ki67 have been linked to TNBC and BLBC as well.48
Second, look for genetic biomarkers that can determine the progression or prognosis,
therapeutic response, and overall survivability to TNBC and BLBC. As an example49,
SFRP1 secretion which correlates with both an aggressive form of breast cancer, has

44

Zhang, Shizhen, Zhen Wang, Weiwei Liu, Rui Lei, Jinlan Shan, Ling Li, and Xiaochen Wang. “Distinct
Prognostic Values of S100 mRNA Expression in Breast Cancer.” Scientific Reports 7, no. 1 (January 4,
2017).
45
Sizemore, Gina M., Steven T. Sizemore and Darcie D. “GABA(A) Receptor Pi (GABRP) Stimulates Basallike Breast Cancer Cell Migration through Activation of Extracellular-Regulated Kinase 1/2 (ERK1/2).”
Journal of Biological Chemistry 289, no. 35 (July 10, 2014): 24102–13.
46
Friedenson, Bernard. (2007). 1471-2407.
47
Yadav, 252-263
48
Ibid
49
Huelsewig, 2014.
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responded positively to neoadjuvant chemotherapy. Other examples include TM4SF1 in
MDA-MB-231 cells, FOXC1, CXRC4, microRNA-761, ARPC2, and SCD1 all of which
are overexpressed in aggressive tumors, and those with a higher likelihood of cellular
migration resulting in metastasis, and low survival.50
Third, identify genetic biomarkers responsible for the development and progression of
TNBC and BLBC, which can also lead to the development of targeted therapeutics. One
notable example51 is SCD1 inhibition that has been reported to reduce the proliferation and
survival of cancer cells. Another is down-regulation and depletion of TRIM28, which has
shown reduction in tumor growth.52 In vivo studies also showed that expression of
AMD3100 or siRNA in MDA-MB-231 could inhibit CXRC4 by under-expressing FOXC,
thus controlling proliferation and metastasis.53

Gene Expression Profiling
DNA microarray technology has been commonly used in many biological purposes such
as gene expression analysis, environmental monitoring, disease characterization. Its
application in gene expression profiling is based on a multiplex technology used to
simultaneously access thousands of genes and identify genes who are differentially
expressed in response to “pathogens” by comparing gene expression between infected and
uninfected cells or tissues.54 A DNA microarray chip consist of an arrayed series of
microscopic spots with immobilized gene-specific DNA oligonucleotides probes. The

50

Fan, Chunni, Ning Liu, Dan Zheng, Jianshi Du, and Keren Wang, 6755–64.
Hosokawa, Yuko, Noritaka Masaki and Shiro Takei, 2017.
52
Czerwińska, Patrycja, Parantu K. Shah and Katarzyna Tomczak et al, 2016.
53
Pan, Hongchao, Zhilan Peng, Jiediao Lin and Xiaosha Ren, 3794–3804.
54
J Mehta. Gene expression analysis in breast cancer. 2010
51
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hybridization of the fluorophore-labeled target onto the probe is usually detected and
quantified to determine relative abundance of target.55
In Affymetrix microarrays, the probes are attached to the substrates by a covalent bond
through a photolithographic process. Each GeneChip contains around 1,000,000 probe sets
that are intended to measure expression for a specific mRNA. Each probe set consists of
probe pairs selected from the target sequence which is derived from one or more mRNA
sequences. The first pair is a perfect match (PM), and the other is mismatch (MM) at the
center. This allow the quantitation and subtraction of nonspecific signals crosshybridization.56 Each gene or transcript consists of 11 probe pairs on the GeneChip, each
name of which has a suffix consisting of the last three or four characters of its name that
describes their ability to bind different genes, splice variants, or their uniqueness as it
shown below57:
•

“_at” hybridizes to unique anti-sense transcript of the gene.

•

“_a_at” all probes cross-hybridize to the same set of sequences from the same gene
family.

•

“_s_at” all probes cross-hybridize to the same set of sequences, but these sequences are
not from the same gene family.

•

“_x_at” at least one probe cross-hybridize with other target sequences.

Microarray technology has been used, since its early development, to identify gene
expression profiles of clinical breast cancer cell lines and specimens. Some of the breast
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cancer sub-groups that have been identified using this technology are the basal sub-type,
and normal-like, luminal A, luminal B, and ERBB2 over-expressing.58
Data Mining in Gene Expression
Data mining can be used with gene expression data to discover patterns and develop
knowledge from biological databases using information technology and computational
techniques. Data mining is an automated data analysis process to find relationships among
data elements. Many of these relationships are not obvious due to the large amount of the
data. Therefore, the researches and scientists can use the data mining techniques to extract
useful information and create knowledge from data to identify correlations between
elements.59
The most common types of microarray data analysis in data mining includes gene selection,
clustering, and classification60. The method of analysis can be determined depending on
the nature of the data and the desired knowledge, using either a descriptive or predictive
model. A descriptive model is used to identify patterns and relationships among the data,
while a predictive model is used to predict the data using existing patterns.
There are several data mining software that can be used to perform data mining, such as
SAS Enterprise Miner, S-Plus, SPSS, IBM Intelligent Miner, SGI MineSet, Microsoft SQL
Server 2000, and Inxight VizServer. However, some biological data mining tools have been
developed, such as Statistics for Microarray Analysis, Affymetrix Data Mining,
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GeneSpring, VectorNTI, Spot Fire, and COMPASS.61 However, in our study SAS
Enterprise Miner software will be used to perform data mining analysis.
SAS Enterprise Miner
SAS Enterprise Miner software is an advanced tool to help users to perform data mining
by developing either descriptive or predictive models. SAS software provides a variety of
data mining tasks, including decision tree, neural networks, link analysis, and linear and
logistic regression.62
Classification
In this study, classification task will be used to perform data mining, which is a process of
learning a function that classifies a data element into two or several classes. Classification
is mostly used in microarray analysis to distinguish diseases or identify the most efficient
treatment for given genetic signature or predict outcomes by performing a predictive model
based on known gene expression patterns.63
The most popular microarray data mining methods for classification include Support
Vector Machine (SVMs), Neural Networks, K-nearest neighbors, classification/Decision
trees, voted classification, weighted gene voting, and Bayesian classification.64 However,
in this study, Artificial Neural Network, Logistic Regression, Decision Tree, Least Angle
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Regression, Bayesian classifier, Gradient Boosting, SVMs, and Random Forrest models
were investigated.
Artificial Neural Networks
Artificial Neural Networks (ANNs) are known as “massively parallel processors,
which tend to preserve experimental knowledge and enable their further use”.65
This model was created based on learning the processes of the neurological function
of the brain and the cognitive system.66 ANNs can provide an extreme complexity
of non-linear functions and predict new observations. The advantage of the parallel
computing environment of ANNs allows users to improve the predictive power
algorithm.67 Applying neural networks enables users to build models with
significantly more lift by allowing more runs to enhance predictive power
incrementally. Additional features of this model include smart defaults for most
neural network parameters, automatic selection of a validation data group, and
automatic standardization of input data and targeted variables.68

Logistic Regression
Logistic regression is a statistical method used to analyze database to classify cases
into the most likely category based on one or more independent variables. In this
study, linear regression cannot be applied since the response variable is discrete.
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Therefore, the regression will predict the odds of its occurrence into two categories
instead of predicting the estimation point. Some of the advantages of using Logistic
Regression includes selecting variables and modeling capabilities for unordered
multinomial data.69

Decision Tree
Decision tree is a classification algorithm starts with a single node, which branches
into possible class predictions the size of the decision tree and classification
accuracy are used to determine the quality of the model analysis. Decision tree uses
mathematical algorithms to identify a variable, also to corresponding threshold for
that identified variable, which is branches the input data into two or more
subgroups. The process is repeated at each node until the tree fully construed. The
spilt search algorithm uses corresponding threshold to maximize the homogeneity
of the outcome subgroups. The most common mathematical algorithm that used to
split the observations into multiple classes are entropy-based information gain, Gini
index, and Chi-square test.70 Finally, the complexity of the tree is optimized via
pruning between training and validation sets. Advantages of Decision trees include
ease of deployment, interpretation and visualization.

Random Forest
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Random Forest is a collection of multiple Decision trees. It is a supervised learning
algorithm that draws random samples from the training dataset to grow the trees of
the forest to the largest extent possible. Trees are trained in parallel and no pruning
is carried out to reduce the size of the trees. In order to categorize new data, it is
first inputted to each of the trees to generate classifications or votes based on the
selected variables. The Random Forest then chooses the final classification
outcome based on the votes scored among all the trees. Some of the advantages of
using Random Forest includes high accuracy, ability to handle large volumes of
multidimensional data, and effective imputation of missing data among others.71

Support Vector Machine
Support Vector Machine (SVM) is a class of machine learning algorithms that
enables users to fit a discriminant function of features such as polynomial and
sigmoid nonlinear kernels to separate one class from another. The nonlinear kernel
transforms the input data to a high dimensional space such that the data space
become separable using two parallel separating hyperplanes. The distance between
the parallel hyperplanes is maximized to the extent in which an optimized
classification model can be realized. An SVM model can also be used for outlier
detection and regression. Some of the SVM’s advantages include effective handling
of unbalanced data and less complexity compared to other classifiers such as ANNs
Previous research has reported that SVM can provide diagnosis ability with high
accuracy in cancer prediction.72
71
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Least Angle Regression
Least Angle Regression (LARS) belongs to a family of generalized linear models
designed to handle high-dimensional data. The algorithm uses a forward stepwise
selection method to identify the optimal variable set; however, instead of adding
variables at each step based on some pre-specified criteria such as adjusted R2 or
Akaike, it selects the variable that is most correlated with the target variable and
then increases the estimated parameters in the least-squares direction until another
variable has as much correlation with the target as the current one has. This
selection process is repeated until none remain to be chosen. Some
major advantages of LARS method are its abilities to handle high dimensional
multi-collinear data and identify the best set of variables. 73

Bayesian Classifier
Bayesian Classifiers are a family of simple probabilistic models that rely on Bayes’
theorem to make class predictions given some data. In Bayesian machine learning,
the input variables are assumed to be independent from each other. To classify a
new observation, it simply estimates the probability that the given data point falls
in a certain class and at the end, chooses the classification that has the highest
probability. Some of the advantages of using a Bayesian Classifier model includes
handling continuous and discrete data, making probabilistic predictions, and
requiring less training data.
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Gradient Boosting
Gradient Boosting is a supervised machine learning algorithm for classification and
regression applications. It is an ensemble of many prediction models using decision
trees. Unlike Random Forest that uses random samples to build independent trees
in parallel, Gradient Boosting builds trees one at a time in a sequential manner such
that each tree is dependent on the residuals of the previous one. Gradient Boosting
first draws a random sample (with replacement) from the original data, trains a
decision tree, and tests its performance on the entire data. Then, the next random
sample is drawn from the original dataset, which includes data points that were
misclassified with the previous tree, and used that to build the second tree, and so
on. This process is repeated until the error function does not change. While Gradient
Boosting provides a very high predictive accuracy, it is less interpretable and prone
to over-fitting due to its greater flexibility in fitting data.74

Data Pre-processing
Data pre-processing for data mining is a critical step to get better results. The data preprocessing is a process of cleaning the data from missing, out of range, or invalid values.
It also provides several features such as understanding what the data represents, exploring
variable statistics and distributions, performing appropriate transformations, and reducing
the data among others. However, data pre-processing is time-consuming, but it is an
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important step to ensure the accuracy of the final results. Data pre-processing takes
approximately up to 80% of the overall time of data mining.75

Measures for Performance Evaluation
There are three common performance measures used in binary classification models. The
first is accuracy which determines the overall classification performance of the model; it
calculates the percentage of correctly classified instances. Second, sensitivity which
measures the proposition of positives that correctly identified. The third is specificity which
measures the proposition of negatives that correctly identified. These performance
measures can be obtained mathematically by the following expressions:
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁

𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =

𝑇𝑃
𝑇𝑃 + 𝐹𝑁

𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =

𝑇𝑁
𝑇𝑁 + 𝐹𝑃

TP, TN, FP, and FN represent True Positive, True Negative, False Positive, and False
Negative, respectively.76 Some studies use the misclassification rate to evaluate
performance accuracy. However, the SAS Enterprise Miner software uses the
misclassification rate in the validation group to rank the models depend on their
performance accuracy.
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A literature survey showed that there are many studies on the characterizing basal-like
breast cancer using statistical analysis. However, we could only find a few studies related
to characterizing BLBC using data mining approaches.
Rody et al.77 conducted a research study regarding TNBC and BLBC by using a database
generated on Affymetrix gene chips for 579 TNBC to perform unsupervised analysis to
propose a definition of metagenes that differentiate molecular subset within TBNC without
considering any clinical outcome. A single platform (Affymetrix U133a AND u133 Plus
2.0 chips) was used for data. However, 394 cases used for discovery, while 185 cases for
validation. 16 metagenes expressions were correlated with survival and multivariate
analysis, including pathological and routine clinical. Those metagenes includes basal-like
phenotype, apocrine/androgen and cludin-low molecular subtypes, or reflected various
non-neoplastic cell population, including blood, stroma, immune cells, adipocytes,
inflammation and angiogenesis within the cancer.
In this study, Rody et al. observed a transparent bimodal distribution of basal-like metagene
score within TNBC. Based on the bimodal distribution, a cutoff (0.0014) was driven to
separate cases into low and high expressions groups by fitting two normal distributions as
shown in Figure 1. As a result, 72.8% of TNBC were classified as BLBC in the discovery
cases, while 69.7% of in validation cases.
In our study, we used the same TNBC database, and the cutoff value (0.0014) of
BLBC to average the important variables. We defined relevant genes from the data as the
average expression of high co-expressed genes groups without considering clinical
outcomes.
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Figure 1. Distribution of the expression of basal-like metagene among TNBC.78
Methodology
It is widely known among data scientists that big data is composed of not only a large
volume of data but also from several different sources, in various formats, from which
greater insights can be gleaned. Therefore, a considerable amount of time and effort needs
to be devoted on data management. Moreover, recent development in high performance
analytical methods has improved our ability to extract meaningful insights from high
dimensional data, which can be investigated using statistical analysis. In this section, we
discuss how these important tasks are accomplished. We describe the data and research
methodology used in this study in the following subsections. Our research methodology
consists of four major phases: data acquisition, data integration, data preprocessing, and
predictive modeling. The analytical methodology is depicted in Figure 2.
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Figure 2. Research Methodology.
However, it is important to mention that other prognostic factors in BC such as age,
histological grade, and tumor size were not considered. The grade has no significant
regard of prognosis since most TNBC cases are high grade. Also age and tumor size
factors are not considered since TNBC subtype is associated with younger age, so the
impact of these two factors for prognosis in TNBC is not yet fully clear.79
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Predictive Modeling

Tabulated Model
Performance Results

Data Acquisition and Integration
Microarray data generation is a very expensive process; therefore, collecting large data
microarray is challenging and requires a substantial amount of resources. To build a large
sample size for this study, it was necessary to pool several datasets from different
laboratories.80 We used multiple public datasets that were built according to the most
widely microarray platform (Affymetrix U133A and U133 Plus 2.0 chips) and included
only cases that were defined as triple negative based on the mRNA expression of ER, PgR,
and HER2 as previously described.81 We compiled a total of 3,488 publicly available breast
cancer gene expression profiles from 28 individual datasets and extracted Affymetrix gene
expression data for 579 TNBC cases.

Data Preprocessing
Data preprocessing is a critical step in data mining, which involves data cleaning, variable
reduction and feature selection. It involves cleaning the data from missing, out of range, or
invalid values. It also allows for a better understanding of what the data represents, to
explore variable statistics and distributions, to perform appropriate transformations, and to
reduce the data, among others. Although data preprocessing is time consuming, it is an
important step in ensuring the accuracy of the results. Data preprocessing takes up to 80%
of the overall time of data mining.
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With microarray data being high dimensional, characterized by many variables and few
observations, it requires feature selection and dimension reduction techniques to remove
genes that do not provide significant incremental information. In this study, we observed
five missing genes in some of the expression datasets, so we excluded those genes from
the analysis. Moreover, we applied various feature selection methods, such as chi-square,
decision tree, Least Angle Regression/ Least Shrinkage and Selection Operator
(LARS/LASSO), principle component analysis (PCA) and ensemble (multi-method)
algorithms, to identify key variables (genes) that could explain the differences in the
observations and could be used to simplify the analysis and prediction of BLBCs. It is
recognized that different feature selection techniques may result in different sets of
biomarkers, that is, different groups of genes highly correlated to a given condition;
however, together, these results can be used to identify driving pathways in basal-like
breast cancer.

Predictive Models
In this study, we used five different feature selection methods (i.e., Chi-square, tree, LARS,
LASSO and ensemble), along with eight predictive models (i.e., Logistic Regression,
Decision tree, Random Forest, Support Vector Machine, Neural Networks, LARS,
Gradient Boosting, and Bayesian Classifier) in an empirical investigation to understand,
characterize and predict BLBCs. The data was divided into 70% for training and 30% for
validation. We performed supervised analysis to define a set of gene markers that
distinguished molecular subsets within TNBCs. The 574 cases were divided into 394 for
discovery and 185 for validation. The initial step was to build stratified datasets for this
analysis. The second step involved applying various popular data mining techniques,
26

including Decision trees, Regression analysis, Random Forest, Neural Network, Least
Angle Regression, Bayesian Classifier, Gradient Boosting, and Support Vector Machine,
to classify BLBC and non-BLBC cases and to identify structures in the molecular data of
the targeted disease. Of all the cases evaluated, 394 were used for training and 185 for
validation. More than 22,000 genes expression data were correlated with survival using
multivariate analysis, including pathological and routine clinical data. Those metagenes
included the basal-like phenotype, apocrine/androgen and claudin-low molecular subtypes,
or reflected various non-neoplastic cell populations, including blood, stroma, immune
cells, adipocytes, inflammation and angiogenesis within the cancer. In summary, 40
different predictive models were built to identify gene signatures and determine which
genes contribute most to BLBC.
We used two types of prediction models in SAS enterprise Miner 12.3 software. The first
type is partial data, which allows us to divide the data set for two groups, 70% for the
data used for train, and 30% for validation. Thus, 579 TNBC cases divided into 394 cases
for the discovery cohort and 185 cases for validation. High-performance data partition
used train data for preliminary model fitting, whereas Validation data used to assess the
adequacy of the fitted model.82
The other type is high-performance data mining (HPDM), which provides several
advantages, including reductions of dimensions for structured inputs and perform
unsupervised variable selection. The high-performance regression aims to predict the
probability of a binary target acquiring an interest event of the assigned link function of
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one or more independent inputs. In our study, we used the cutoff value of 0.0014 from
Rody et al. to average the crucial variables and assigned 1 to be BLBC class, and 0 for
non-BLBC.
After implementing these two types, the following models utilized: Artificial Neural
Network, Logistic Regression, Decision Tree, Least Angle Regression, Bayesian
Classifier, Gradient Boosting, Support Vector Machine, and Random Forest along with
these nodes.
Result
Performance Evaluation of the models
A summary of the model’s performances on 22,000 gens of 579 TNBC cases used in this
study is shown in Table 1 The table includes the misclassification, accuracy, sensitivity,
and specificity rates for each classifier. According to the result, the neural network model
shows the highest average accuracy compared to other methods. The Gradient Boosting
and Logistics Regression models have very close values of accuracy, while the Decision
tree has the lowest average accuracy.
Table 1. Models' performance Evaluation.
Feature Selection method: Chi-Square
Misclassification
Method
0.0455
Decision Tree
0.0511
LARS
0.0455
Neural Network
0.0398
Logistics Regression
0.0230
SVM
0.0341
Gradient Boosting
0.0341
Random Forrest
0.0520
Bayesian Classifier
Feature Selection method: Decision Tree
Misclassification
Method

Accuracy

Sensitivity

Specificity

0.9545

0.9922

0.8542

0.9489

0.9766

0.8750

0.9545

0.9688

0.9167

0.9602

0.9688

0.9375

0.9770

0.9921

0.9362

0.9659

0.9922

0.8958

0.9659

0.9922

0.8958

0.9480

0.9680

0.8958

Accuracy

Sensitivity

Specificity
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0.0517
0.9483
0.9921
Decision Tree
0.0345
0.9655
0.9764
LARS
0.0556
0.9444
0.9398
Neural Network
0.0287
0.9713
0.9843
Logistics Regression
0.0230
0.9770
0.9921
SVM
0.0230
0.9770
0.9843
Gradient Boosting
0.0402
0.9598
0.9921
Random Forrest
0.0575
0.9425
0.9528
Bayesian Classifier
Feature Selection method: LARS/LASSO
Misclassification
Accuracy
Sensitivity
Method
0.0625
0.9375
0.9922
Decision Tree
0.0511
0.9489
0.9766
LARS
0.0118
0.9882
0.9918
Neural Network
0.0345
0.9655
0.9764
Logistics Regression
0.0455
0.9545
0.9844
SVM
0.0172
0.9828
0.9921
Gradient Boosting
0.0455
0.9545
0.9844
Random Forrest
0.0625
0.9375
0.9531
Bayesian Classifier
Feature Selection method: Principal Component Analysis
Misclassification
Accuracy
Sensitivity
Method
0.1207
0.8793
0.9606
Decision Tree
0.0460
0.9540
0.9764
LARS
0.0345
0.9655
0.9764
Neural Network
0.0402
0.9598
0.9764
Logistics Regression
0.0517
0.9483
0.9843
SVM
0.0805
0.9195
0.9685
Gradient Boosting
0.0707
0.9293
0.9781
Random Forrest
0.1034
0.8966
0.9370
Bayesian Classifier
Feature Selection method: Multi-method
Misclassification
Accuracy
Sensitivity
Method
0.0862
0.9138
0.9606
Decision Tree
0.0230
0.9770
0.9921
LARS
0.0172
0.9828
0.9843
Neural Network
0.0287
0.9713
0.9843
Logistics Regression
0.0287
0.9713
0.9843
SVM
0.0172
0.9828
0.9921
Gradient Boosting
0.0230
0.9770
0.9921
Random Forrest
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0.8298
0.9362
0.9574
0.9362
0.9362
0.9574
0.8723
0.9149
Specificity

0.7917
0.8750
0.9792
0.9362
0.8750
0.9574
0.8750
0.8958
Specificity

0.6596
0.8936
0.9362
0.9149
0.8511
0.7872
0.7872
0.7872
Specificity

0.7872
0.9362
0.9787
0.9362
0.9362
0.9574
0.9362

Bayesian Classifier

0.0230

0.9770

0.9843

0.9574

The results indicate that most predictive models gained prediction accuracy from a multimethod feature selection approach, compared to each individual approach. We found no
evidence that a certain feature selection method is particularly well suited for use in
combination with a specific predictive model. However, Decision tree, Gradient Boosting,
Random Forest, and Bayesian Classifier did not gain much prediction accuracy from one
principal component compared to another.

The feature selection analysis revealed over 500 genes, which appear to be associated
with BLBC. Table 2 summarizes the top 40 genes from pathways, which are associated
with BLBC. These genes are sorted according to the number of times they were selected
by the feature selection algorithms as input for predictive models..
Table 2. Top 40 Genes Associated to BLBC.
Gene
_205044_at
_220425_x_at
_204855_at
_213260_at
_205157_s_at
_209800_at
_202037_s_at
_206560_s_at
_209387_s_at

Gene Description
Gamma-aminobutyric acid (GABA), A receptor, pi(GABRP)
ROPN1B
Serpin peptidase inhibitor, clade B (ovalbumin), member 5 (SERPINB5)
Forkhead box C1 (FOXC1)
Keratin 17, type I (KRT17)
keratin 16, type I (KRT16)
Secreted frizzled-related protein 1 (SFRP1)
Melanoma inhibitory activity (MIA)
Transmembrane 4 L six family member 1 (TM4SF1)

_219768_at
_209504_s_at

Count
14
14
11
11
10
10
9
9
9

V-set domain containing T cell activation inhibitor 1 (VTCN1)
Pleckstrin homology domain containing, family B (evectins) member 1
(PLEKHB1)
_211682_x_at UDP glucuronosyltransferase 2 family, polypeptide B28 (UGT2B28)
_212236_x_at JUP
_60474_at
Fermitin family member 1 (FERMT1)
_201820_at
Keratin 5, type II (KER5)

8
7

_208998_at

6

Uncoupling protein 2 (mitochondrial, proton carrier) (UCP2)
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7
7
7
6

_209126_x_at
_210473_s_at
_202036_s_at
_202504_at
_204751_x_at
_213680_at

Keratin 6B, type II (KRT6B)
Adhesion G protein-coupled receptor A3 (ADGRA3)
Secreted frizzled-related protein 1 (SFRP1)
Tripartite motif-containing 29 (TRIM 29)
DSC2
Keratin 6B, type II (KRT6B)

6
6
5
5
4
4

_217901_at
_218868_at
_200832_s_at
_201485_s_at
_202342_s_at
_203058_s_at
_204268_at
_205265_s_at

Desmoglein 2 (DSG2)
ARP3 actin-related protein 3 homolog B (yeast) (ACTR3B)
Stearoyl-CoA desaturase (delta-9-desaturase) (SCD)
Reticulocalbin 2, EF-hand calcium binding domain (RCN2)
Tripartite motif containing 2 (TRIM 2)
3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2)
S100 calcium binding protein A2 (S100A2)
SPEG complex locus (SPEG)

4
4
3
3
3
3
3
3

_207397_s_at
_208063_s_at
_209351_at
_209791_at
_209842_at
_210074_at
_212147_at
_214598_at
_219301_s_at
_219795_at

Homeobox D13 (HOXD13)
Calpain 9 (CAPN9)
Keratin 14, type I (KRT14)
Peptidyl arginine deiminase, type II (PADI2)
SRY (sex determining region Y)-box 10 (SOX10)
Cathepsin V (CTSV)
Nonsense mediated mRNA decay factor (SMGS)
Claudin 8 (CLDN8)
Contactin associated protein-like 2 (CNTNAP2)
Solute carrier family 6 (amino acid transporter), member 14 (SLC6A14)

3
3
3
3
3
3
3
3
3
3

Neural Network (ANNs)
Neural Network (ANNs) considered to be one of the powerful methods to analyze the
data with high accuracy. In this study, this model identified 12 important genes that
correlate with BLBC. Figure 1 shows the equation’s line between those gens and BLBC
class. Those gens are Transglutaminase 2(TGM2), Discs, large homolog 5
(Drosophila)(DLG5), Cytochrome b5 reductase 1(CYB5R1), Desmocollin 2(DSC2),
Transmembrane protein 5(TMEM5), GDP-mannose 4,6-dehydratase(GMDS), Gammaaminobutyric acid (GABA) A receptor, pi(GABRP), Phospholipase A2, group IB
(pancreas)(PLA2G1B), Junction plakoglobin(JUP), Chromosome 19 open reading frame
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73(C19orf73), Rhophilin associated tail protein 1B (ROPN1B), and Nuclear factor I/X
(CCAAT-binding transcription factor) (NFIX).

Figure 3. Neural Network Model (ANNs).
In Figure 3, the small blue circles on the far left of the link graph represent all variables
input (genes), which have correlation with BLBC. The target variable placed on the far
right of the link graph; which is in this case represents class=1 (the BLBC subtype). H1,
H2, and H3 are the hidden layers. The color and the width of the linked lines indicate
how secure the connection is of that particular line; the thinner, blue lines represent a
smaller value of the weight of that connection, and the thicker red line indicates a
substantial magnitude value of the link connection.83
In Figure 3, chromosome 19 open reading frame 73(C19orf73), phospholipase A2, group
IB (pancreas)(PLA2G1B), and GDP-mannose 4,6-dehydratase(GMDS) have pink and
thicker lines, which means that the magnitude of the weight of the connection is
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significant. These genes linked to hidden “layer 3” (H3); H3 linked to class=1 (BLBC) by
the red, thicker line, which shows a strong connection. As a result, C19orf73, PLA2G1B,
and GMDS have a higher correlation to BLBC, followed by CYB5R1 and JUP.

These 12 genes are known to be involved in various aspects of TNBC’s pathogenesis. For
instance, TGM2 is involved in TNBC epithelial-to-mesenchymal transition (EMT), which
promotes their migratory and invasive properties, and controls their chemoresistance and
immune escape.84 In addition, TGM2 expression is frequently up-regulated during
inflammation and wounding. Emerging evidence indicates that TGM2 expression is
aberrantly up-regulated in multiple cancer cell types, particularly those selected for
resistance to chemotherapy and radiation therapy and those isolated from metastatic site.85

Loss of DLG5 promotes TNBC cell proliferation by inhibiting the Hippo signaling
pathway, increasing nuclear YAP expression, and inducing EMT.86 DLG5 plays important
roles in epithelial cell polarity maintenance, precursor cell division, cell proliferation, cell
migration and invasion, and transmission of extracellular signals to the membrane and
cytoskeleton. Failure in establishment and maintenance of epithelial cell polarity
contributes to tumorigenesis. Loss of expression and function of cell polarity proteins is
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directly related to epithelial cell polarity maintenance.87 Another gene whose expression
correlates with EMT is CYB5R1, which is a widely expressed oxidoreductase involved in
oxidative stress reactions and drug metabolism. Although its specific role in cancer
progression is still not clear, its transcriptional level expression strongly correlates with
EMT in colorectal cancer.88
The DSC2 protein is a major component of desmosomes, which provide strength and
stability to tissues. This protein has been shown to be highly expressed in TNBCs, being
able to significantly predict patient survival, and suggesting their role in the aggressiveness
seen in these tumors.89 TMEM5 is a type II transmembrane protein, thought to be a
glycosyltransferase involved in the glycosylation of dystroglycan, which is part of a
complex that links the extracellular matrix to the cytoskeleton. Aberrant glycosylation
leads to the disruption of this link thus favoring migration and invasiveness seen in many
tumors.90 TMEM5 is significantly over-expressed in BRCA1-mutated breast cancer cells,91
with these type of mutations occurring in TNBC more frequently than in the general
population,92 93. GMDS is involved in the process of cellular fucosylation of glycoproteins,
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which involved in the functional regulation of adhesion molecules and growth factor
receptors, with high levels of fucusylation being reported in various types of cancer.94 This
has been associated with TNBC and EMT, making GMDS a potential player in this
process.95
Expression of GABRP is shown to be associated with the BLBC/TN subtype, and herein,
we reveal its expression also correlates with metastases to the brain and poorer patient
outcome.96 PLA2G1B are esterases that preferentially cleave glycerophospholipids into
biologically active fatty acids and lysophospholipids, and are differentially expressed in
breast cancer.97 These active lipids have biological functions relevant to cancer progression
and each can be further metabolized into additional functional biomolecules.98 These active
lipids modulate cellular differentiation, proliferation, apoptosis and senescence, whose
dysregulation can result in the uncontrolled growth and metastasis seen in tumors.
JUP is a cell adhesion protein, was recently reported as a determinant of circulating tumor
cells types, single or clustered. This protein could be functioning as a double-edge sword,
since loss of its expression leads to increased motility of epithelial cells, thereby promoting
EMT and further metastasis. However, studies also show that JUP can function as an
oncogene, with high expression of JUP resulting in clustered tumor cells in circulation with
high metastatic potential in breast cancer and shortened patient survival. In addition, JUP
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may be a potential prognostic biomarker that can be exploited to develop as a therapeutic
target for breast cancer.99 Although C19orf73 is a hypothetical protein that has not been
characterized, a search of the GEO Profiles database100 revealed that it is overexpressed in
TNBC (GEO accession GDS4069.101
Ropporin is a sperm-specific protein and is associated with sperm motility. Its expression
was also found in motile cilia helping them to move in one direction in a synchronized
pattern. Ropporin (ROPN1 and ROPN1B) was identified as differentially-expressed in
several gene lists commonly associated with bad prognosis in our breast cancer
investigation.102 The Nuclear Factor I (NFI) family of site-specific DNA binding
proteins functions in adenoviral DNA replication and in the regulation of transcription of
a large variety of cellular and viral genes. This family is comprised of four genes in
vertebrates (NFIA, NFIB, NFIC and NFIX), whose encoded proteins interact with DNA as
homo- or hetero-dimers. They bind to the palindromic sequence TTGGC(N5)GCCAA with
high affinity, resulting in transcriptional activation or repression, depending on the cellular
context and regulatory region . Binding sites for these factors have been identified
in promoter, enhancer and silencer regions of a plethora of genes expressed in almost every
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organ and tissue.103 It’s been found that expression is increased in TNBC across the datasets
104

in a study but NFIX needs further studies.

Logistic regression
Logistic regression is another technique that we used in this analysis. In figure 4, the
chart shows the relative importance to BLBC for 12 genes sorted in descending order.
The horizontal axis is the correlated genes, while the vertical axis shows the value of the
correlation range from 0-1 since the binary targets have two levels, where 1 represents
the essential variables.
According to the results, gamma-aminobutyric acid (GABA) A receptor, pi (GABRP),
has the highest correlation with BLBC based on the relative importance value; followed
by JUP, ROPN1B, DSC2, TMEM5, GMDS, NFIX, C19orf73, DLG5, CYB5R,
PLA2G1B, and TGM2, respectively.
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Figure 4. Logistic regression model.

Decision Tree
The decision tree model shows gene expressions in ascending order regard on the
correlation to BLBC subtype. Each node includes some general properties such as the
node Id, statistic information for both the train and validation group. As mentioned
earlier, 1 represents the BLBC class and 0 for the non-BLBC class.
In figure 5, Node 1 represents gamma-aminobutyric acid (GABA) A receptor,
pi(GABRP) as the highest correlated gene to BLBC; reflecting that a 72.73% of TNBC
classified as BLBC in the validation group, and 27.27% are non-BLBC. On the other
hand,72.95% are BLBC of the training group, and 27.05% are non-BLBC. However, two
split nodes resulted according to the rule of “if values are less or more than the cutoff
value (0.0014)”. The corresponding genes are given in Table 3. However, based on a
research was done to investigate the impact of gene expression on TNBC, all these
identified genes were up-regulated in TNBC (more details are discussed in discussion
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section). Therefore, it can not be concluded if any up or down regulation is associated
with TNBC from discussion model.
Table 3. Gene importance by Decision Tree model.
Gene

Importance

Description

GABRP

1

gamma-aminobutyric acid (GABA) A receptor, pi.

JUP

0.5097

junction plakoglobin.

ROPN1B

0.4033

rhophilin associated tail protein 1B.

DSC2

0.3393

desmocollin 2.

TMEM5

0.2383

transmembrane protein 5.

Figure 5. Decision Tree model.
Discussion tree algorithm, started single node by classifying GABRP gene as most
important gene with score 1 out of 1 as shown in table 3. Then it branches to other
possible classification based on the average importance value. Therefore, if it less than
0.0041 the second important gene is JUP gene as single node 2, from node 2 at average of
0.0093 another node branched to predict another relevant gene which is ROPN1B. at
each node the statistical information is provided as mentioned before.
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Random Forest
Random Forest model targeted 10 genes. Table 4 includes the number of splitting rules
for each gene. However, As the rules splits more, the importance of the gene increases.
Some genes have the same number of splitting rules, which means that those genes have
the same level of importance.
Table 4. Random Forest with variable selection enabled.
Variable Name

Number of splitting rules

Gene

_202504_at

15.0

TRIM 29

_205157_s_at

12.0

KRT17

_202342_s_at

9.0

RCN2

_204855_at

9.0

SERPINB5

_206560_s_at

9.0

MIA

_214404_x_at

8.0

SPDEF

_219615_s_at

8.0

KCNK5

_202431_s_at

7.0

MYC

_205044_at

7.0

GABRP

_209504_s_at

6.0

PLEKHB1

Table 4 ranked the most important gene as following: TRIM2, Keratin 17, type I
(KRT17), Reticulocalbin 2, EF-hand calcium binding domain (RCN2), Serpin peptidase
inhibitor, clade B (ovalbumin), member 5 (SERPINB5), Melanoma inhibitory activity
(MIA), SAM pointed domain-containing Ets transcription factor (SPDEF), Potassium
channel subfamily K member 5 (KCNK5), Proto-Oncogene, BHLH transcription factor
(MYC), GABRP, then Pleckstrin homology domain containing, family B (evectins)
member 1 (PLEKHB1).
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Least Angle Regression
Figure 6 represents Least angle regression model; the method estimates the correlation
between the gen and BLBC. The blue bars represent a positive correlation with BLBC, so
the highest gene expression estimates, the highest chance to be classified as BLBC. The
red bars represent a negative correlation with BLBC. However, UDP
glucuronosyltransferase 2 family, polypeptide B2(UGT2B28), and cytoplasmic linker
associated protein 1(LASP1) have a negative correlation with BLBC.

Figure 6 Least angle regression model.

In figure 6, the most critical genes based on the estimated value, are sorted in ascending
order as following: ROPN1B, Forkhead box C1 (FOXC1), GABRP, Secreted frizzledrelated protein 1 (SFRP1), keratin 16, type I (KRT16), SERPINB5, PLEKHB1, KRT17,
MIA, Fermitin family member 1 (FERMT1), V-set domain containing T cell activation
inhibitor 1 (VTCN1), Keratin 5, type II (KRT5), Keratin 6B, type II (KRT6B),
Desmoglein 2 (DSG2), Vestigial like family member 1(VGLL1), following by EPH
receptor B3(EPHB3).

41

Bayesian classifier
Bayesian Classifier is another method used to analyze the data. This model shows the genes
most relevant to BLBC. The result of this model is represented in Table 5, where the most
important 12 genes are presented.
Table 5. Gene Ranking (importance) using Bayesian Classifier.
Variable

Name of the gene

Order

Score

_220425_x_at

ROPN1B

1.0

-149.8388379843322

_205044_at

GABRP

2.0

-152.06028382414326

_212236_x_at

JUP

3.0

-178.30128029698253

_204751_x_at

DSC2

4.0

-197.10605719691765

_204875_s_at

GMDS

5.0

-250.02823043246084

_202263_at

CYB5R1

6.0

-252.2041273457195

_222339_x_at

NFIX

7.0

-255.19927200917277

_201042_at

TGM2

8.0

-256.2482325776195

_220151_at

C19orf73

9.0

-257.503065161863

_201681_s_at

DLG5

10.0

-260.21558211552104

_206311_s_at

PLA2G1B

11.0

-261.0894822749076

_204808_s_at

TMEM5

12.0

-261.13372976549573

Gradient Boosting
Gradient Boosting is the model with the highest accuracy performance in this study
(97.15%). This model shows 12 most important genes, which have a high correlation with
BLBC, as shown in Table 6. According to the results, ROPN1B is the most important gene
expression, while GMDS in the least important among those 12 genes.
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Table 6. Correlated genes with gen selection enabled.

NAME

GENE

LABEL

NRULES

IMPORTANCE

VIMPORTANCE

RATIO

_220425_x_at ROPN1B

220425_x_at

24

1

1

1

_205044_at

205044_at

13

0.976866

0.843971

0.863958

_212236_x_at JUP

212236_x_at

20

0.6846

0.570677

0.833592

_204751_x_at DSC2

204751_x_at

7

0.403207

0.437559

1.085197

_201042_at

TGM2

201042_at

3

0.093932

0

0

_201681_s_at

DLG5

201681_s_at

2

0.093776

0

0

_202263_at

CYB5R1

202263_at

2

0.084822

0

0

_204808_s_at

TMEM5

204808_s_at

2

0.062419

0

0

_220151_at

C19orf73

220151_at

1

0.061109

0.060705

0.993387

_222339_x_at NFIX

222339_x_at

2

0.059511

0

0

_206311_s_at

PLA2G1B

206311_s_at

1

0.032846

0

0

_204875_s_at

GMDS

204875_s_at

0

0

0

GABRP

Summary
Table 7 shows all the relevant genes to BLBC with the model’s names since some genes
resulted as having association with BLBC in more than two models. The table helped to
identify the most important genes. Since each model has a unique algorithm to classify
those genes, the probability of the identifying the most correlated genes will high.
Table 7. Gene’s list with models.
Gene

Models
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ROPN1B

Neural Network, Logistic Regression, Decision Tree, Least Angle
Regression, Bayesian classifier, Gradient Boosting.

GABRP

Neural Network, Logistic Regression, Decision Tree, Random Forest,
Least Angle Regression, Bayesian classifier, Gradient Boosting.

TGM2

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

JUP

Neural Network, Logistic Regression, Decision Tree, Bayesian
classifier, Gradient Boosting.

DSC2

Neural Network, Logistic Regression, Decision Tree, Bayesian
classifier, Gradient Boosting.

TMEM5

Neural Network, Logistic Regression, Decision Tree, Bayesian
classifier, Gradient Boosting.

GMDS

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

CYB5R1

Neural Network, Bayesian classifier, Gradient Boosting.

DLG5

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

PLA2G1B

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

C19orf73

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

NFIX

Neural Network, Logistic Regression, Bayesian classifier, Gradient
Boosting.

TRIM 29

Random Forest

KRT17

Random Forest, Least Angle Regression.

RCN2

Random Forest

SERPINB5

Random Forest, Least Angle Regression.

MIA

Random Forest, Least Angle Regression.

PLEKHB1

Random Forest, Least Angle Regression.

SPDEF

Random Forest

KCNK5

Random Forest
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MYC

Random Forest

KRT16

Least Angle Regression

FERMT1

Least Angle Regression.

VTCN1

Least Angle Regression.

DSG2

Least Angle Regression.

KRT6B

Least Angle Regression.

EPHB3

Least Angle Regression.

VGLL1

Least Angle Regression.

SERP1

Least Angle Regression.

FOXC1

Least Angle Regression.

KRT5

Least Angle Regression.

Discussion
Based on the results, ROPN1B and GABRP are the most correlated genes where
ROPN1B shows as the most relevant gene to BLBC both in Gradient Boosting and
Bayesian models with the average of 96.01% accuracy, and third associated gene in
Logistic regression and Decision tree with average of 95.87% accuracy. GABRP also is a
robust, relevant gene to BLBC; it is the first important gene in both Logistic regression
and Decision tree with an average of 95.87% accuracy, and the 2ed in Gradient Boosting
and Bayesian models with average of 96.01% accuracy. However, the Gradient Boosting
model shows the highest accuracy of 0.971591 compared to other methods.
We systematically searched the web of science databases, PubMed, and Journals to
identify studies which support our results. Table 8 represents the relevant studies for each
gene. In the included studies, the expression of ROPN1B, GABRP, JUP, DSC2,
TMEM5, PLA2G1B, TRIM 29, RCN2, EPHB3, SERPINB5, MIA, SPDEF, KCNK5,
MYC, KRT5, KRT16, KRT6B, KRT17, FERMT1, EPHB3, VGLL1, SFRP1, and
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FOXC1 were up-regulated in breast cancer as general while the down-regulated
CYB5R1, DLG5, and C19orf73 expressions were associated with BC.
Table 8. Gene’s list with relevant studies supports our results.
Gene

Relevant studies

ROPN1B

According to Jai Mehta study105, ROPN1B was significantly upregulated in breast cancer patients who relapsed, BC patients who did not
survive for more than five years, BC patients who relapsed within five
years, and patients with negative Estrogen Receptor tumors. Besides,
ROPN1B up-regulated in a sub-group of ER-negative BC with a high
incidence of relapse. Another study106 also reported an up-regulated
expression of ROPN1B in ER-/HER2- BC tumors. However, It is it is
crucial to investigate the role of ROPN1B in BC since little is known
about this protein.

GABRP

According to another study107, about decade ago, GABRP expression
was reported to correlate with BLBC. Moreover, GABRP gene not only
correlates with BLBC, but also correlated with metastatic dissemination
to the brain, showing poorer prognosis. They reported that silencing
GABRP in BLBC cells decreased migration, BLBC-associated
cytokeratins, and ERK1/2 activation. Furthermore, GABRP expression
was up-regulated in ER-/HER2- BC tumors based on Bioinformatics
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107
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analysis.108 Therefore, knocking down GABRP expression may be a new
approach for BLBC treatment.109
TGM2

Tissue-type transglutaminase 2(TGM2) is a pro-inflammatory protein
associated with the resistance of drugs and the metastatic phenotype in
BC. TGM2 reported110 as an essential link in interleukin (IL)-6 mediated
cancer cell aggressiveness, it is also an important mediator of distant
metastasis. Suppressing TGM2 appears to increase the chemo-sensitivity
of cancer cells that were treated with drugs and could be a therapeutic
approach.111

JUP

an investigation112 for breast cancer survival and Plakoglobin (JUP) was
done by using multivariate and univariate analyses. JUP might be a
function of a double-edged sword molecule. Decrease in JUP expression
causes an increase of motility of epithelial cells. Therefore, epithelialmesenchymal transition is prompted and further cancer metastasis. The
same study shows that JUP is an oncogene function. High JUP
expression causes in clustered tumor cells with high metastatic potential
in BC and reduces the probability of patient survival.
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DSC2

The DSC2 protein is a major component of desmosomes, which provides
strength and stability to tissues. A study113 of gene expression microarray
analysis was performed by unsupervised hierarchical clustering to
identify relevant genes that was expressed differentially between BLBC
and non-BLBC. The results show that DSC2 overexpressed in the TNBC
subtype.
Furthermore, DSC2 is a part of a six-gene signature that predicts
metastasis of BC lung.114 A later study115 has been reported that DSC2 is
associated with BLBC. This protein has been shown to be highly
expressed in TNBCs, being able to significantly predict patient survival,
and suggesting their role in the aggressiveness seen in these tumors.116

TMEM5

TMEM5 significantly up-regulated in BRCA1, it expressed about three
times more in BRCA1 mutated cell line (SL) compared to BRCA1 wildtype cell line (BS). 117 118

PLEKHB1

PLEKHB1 known also as KPL-1and KP-1 is a human breast cancer cell
line based on the malignant effusion of a patient with breast cancer.119
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GMDS

GMDS is involved in the process of cellular fucosylation of
glycoproteins, which is involved in the functional regulation of adhesion
molecules and growth factor receptors, with high levels of fucusylation
being reported in various types of cancer.120 This has been associated
with TNBC and EMT, making GMDS a potential player in this
process.121

CYB5R1

Estrogen-related receptor alpha (ERRα) is overexpressed in different
types of tumors, including breast tumors (tripe-negative breast cancer). It
is associated with more aggressive tumors, worse outcomes, and
increased rate of recurrence.122 Taken together with another study123
suggested that CYB5R1 was significantly down-regulated based on
microarray analysis of ERRα-silenced HCT116 cells. Along with our
results, we suggest that CYB5R1 may correlate with TNBC, Basal-like
breast cancer.

DLG5

DLG5 is another gene that correlated with BLBC whose loss of expression
resulted in Hippo pathway inhibition through the induction of Scribble
mislocalization and down regulating its expression. Also, loss of DLG5
leads to increasing Yes-associated protein(YAP) nuclear localization; in
summary, loss of DLG5 expression promoted breast cancer malignancy so
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a more effective tumor therapy can be achieved by over expression of
DLG5.124 This study along with previous studies show that DLG5 acts
as a tumor suppressor in breast cancer125, and its expression is up-regulated
in BLBC according to our study.
PLA2G1B

The overexpression of PLA2G1B is associated with a high level of
Choline. However, a high level of Choline and Phosphocholine have
been demonstrated in BC cells. Worth to mention, most of the xenograft
models were BLBC.126

C19orf73

Huayan et al.127 examined the integrin β4 expression in breast tumors,
and its function in cancer stem cells regulation. As it is known that
integrin β4 contributes to BC tumors in terms of invasion, formation, and
metastasis. According to her data, β4 expression expressed
heterogeneously in BC; but not directly expressed in cancer stem cells
but correlated with the population of basal epithelial. However, c19orf73
observed as down-regulated in β4 knockout cells.

NFIX

A study128 used a DNA methylation MIRA microarray analysis to
identify biomarkers for early detection of BC. According to their results,
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NFIX was one of three genes that was first identified to be
hypermethylated in BC.
TRIM 29

A study reported that an overexpression of exogenous microRNA-761
amplified the TNBC cell proliferation, migration, invasion, and colony
formation in vivo. MicroRNA-761 represses TRIM29 expression,
inducing aggressive phenotypes in TNBC cells. However, the
overexpression of TRIM29 reversed the TNBC cell proliferation and
invasion.129 TRIM29 may act as a regulatory factor in cancer tumors. In
support of this research, a recent study had been reported that the upregulated of TRIM29 expression is associated with ER-/HER2- BC
tumors.130 Using TRIM29, there needs to be more studies conducted in
breast cancer cells because TRIM29 suppresses invasiveness by downregulating the expression of TWIST1, whereas TRIM29 promotes cell
invasion by regulating MMP-9 in lung cancer.131

RCN2

RCN2 indicated in many reports an up-regulated in various types of
cancer tumors including breast, colorectal, kidney, and liver cancer.132

SERPINB5 Many studies claim that the loss of SERPINB5 expression is associated
(MASPIN)

with breast cancer. One of the studies133 reported that the epithelial gene
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SERPINB5 significantly inhibited cell motility. Another report134
suggested that SERPINB5 has involved in determining the metastatic
potential of BC cell lines. Furthermore, SERPINB5 expression was
reported to correlate with BLBC rather than to be a myoepithelial
markers in TNBC. MASPIN may play a substantial role in regulating
processes that are associated with the progression and metastatic cascade
of TNBC and could present an exclusive and specific target for the
diagnosis and therapeutic intervention of TNBC.
MIA

(MIA) is known as a small secreted protein expressed in cartilage; a recent
study reported that it is overexpressed in breast cancer.135In situ expression

patterns study136, MIA expression has been observed at higher levels in
breast cancer and reported to have a much bolder expression in
malignant epithelial neoplasm. A recent study supports the correlation
link between MIA and TNBC by reporting an overexpression of MIA in
ER-/HER2- BC tumors.137
SPDEF

Androgen receptor expression overexpressed in approximately 70% of
breast cancer. SPDEF is one of the Androgen receptor-related genes,
which reported as overexpressed in molecular apocrine tumors.138
However, PDEF expression restricted to epithelial cells in the breast.139
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KCNK5

Overexpression of KCNK5 has been observed to have a significant
correlation with TNBC; however, it failed to meet the significance
criteria to be relevant to BLBC.140 Conversely, Clarker et al. suggested
that up-regulated KCNK5 expression is associated with poor outcomes in
BLBC.141

MYC

Based on Immunohistochemical analysis,142 high expression of MYC
was reported to associate with the BLBC tumor subtype. Furthermore,
other studies of the transformation of epithelial cells show the correlation
between MYC and BLBC.143 144

KRT5,

KRT5, KRT16, KRT6B and KRT17 are early detection biomarkers for

KRT16,

TNBC tumors known as Basal-like cytokeratins.145 A recent

KRT6B

investigation146 found that KRT6B, KRT16, KRT17, and KRT81 were

and

up-regulated and correlated with cancer cell proliferation and invasion

KRT17

pathways. Further support of the link between KRT16 and BLBC, a
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study147 of circulating tumor cells reported that overexpression of
KRT16 in BLBC cell lines was associated with shorter relapse-free
survival.
FERMT1

Based on bioinformatics analysis from microarray data, FERMT1 upregulated in ER-negative/HER2-negative breast cancer tumors.148
Another study149 reported that FERMT1 was predictive of BC lung
metastases, which in gene expression of 23 metastases of BC tumors
were analyzed.

VTCN1

A report150 suggests that VTCN1 expression was significantly different
in BC tumors compared to normal tumors, which may be involved in the
progression of BC and metastasis. Also, they suggested that VTCN1
expression could be an early-biomarker for BC.

DSG2

DSG2 expression was reported to present in the invasion and motility of
BC cells; also, it may act as a tumor suppressor molecule.151

EPHB3

Ephrin B receptors are associated with complex signally pathways in
cancer. A study conducted by using microarray data for 3,554 patients
had reported that overexpression of EPHB3 was significantly associated
with worse survival in BC patients. From the same study findings,
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EPHB3 was also reported to have an association with the improvement
of relapse-free survival with BLBC.
VGLL1

According to bioinformatics analysis results, Overexpression of VGLL1
associated with ER-negative/HER2-negative breast cancer.152

SFRP1

SFRP1 has been suggested to be a potential prognostic marker153 .
Moreover, an increased secretion of this protein has correlated with
higher expression in BLBC cell lines. Furthermore, an study showed that
SFRP1 strongly correlates with the TNBC subtype and that SFRP1 might
be used as a marker classifying patients to positively respond to
neoadjuvant chemotherapy.154

PADI2

PADI2 expression correlates with breast cancer, where PADI2
expression contributes to migration of abnormal in breast cancer tumor
cells.155

HOXD13

It is related with positive LNM and tumor size in breast cancer. In
addition, low levels of HOXD13 correlates with poorer survival in breast
cancer patients.156
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TM4SF1

A high level of TM4SF1 was shown in TNBC tissues, suggesting that
TM4SF1 might be a biomarker of TBNC.157

FOXC1

A higher level of FOXC1 expression boosts TNBC metastasis by
activating the transcription of CXRC4. However, in a zebrafish tumor,
either siRNA or AMD3100 in MDA-MB-231 cells can inhibit CXRC4
by down-regulated FOXC1.158 According to an analysis of microarray
data sets for 2,073 breast cancer patients, FOXC1 suggested to be a
diagnostic and prognostic biomarker, and could be used as a therapeutic
target for the BLBC subtype.159 FOXC1 is a desirable avenue for further
research as a possible therapeutic target in cancer treatment using
nanomedicine.

Another study shows that UGT2B28 expression in a breast cancer cell line, suggests its
role in androgen and estrogen metabolism.160 There is currently no study showing a
correction between UGT2B28 and the TNBC subtype. According to related studies,
UCP1, 2 and 3 act as inductors for autophagy and mitochondrial dysfunction in breast
cancer cells, which cause a significant reduction in tumor growth.161 However, as with
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UGT2B28, there are no published results available to support UPC2’s correlation with
either TNBC or BLBC.
Conclusions
Triple-negative breast cancer (TNBC) constitutes approximately 20%-25% of all breast
cancer cases with poor prognoses, with Basal-like breast cancer (BLBC) being a subtype
representing 72.8% of TNBC. Classifying BLBC subtypes is of paramount importance for
proper diagnosis, with direct clinical implications by dictating the most effective course of
treatment.
Although prior research has shown that profiling breast cancers using gene expression
data has been useful in investigating and defining prognosis and therapy, little attention
has been paid to the molecular characteristics of the basal-like group of breast cancers.
Most (if not all) microarray studies of BLBC have been based on small sample size and
conducted in isolation from one another in most cases, thus limiting the generalizability
of the results. To illustrate the significance of data integration in microarray gene
profiling of basal-like breast cancers. in this study, we combined over 24,000 genes of
579 TNBC patients from several TNBC gene expression datasets to identify several
important gene signatures in BLBC. A series of different predictive models were built to
analyze the data with acceptable accuracy rates. The high dimensionality of the resultant
dataset negatively affected the models’ performance due to overfitting. To address this
issue, several feature selection algorithms were applied to the combined microarray data
in order to identify informative genes for building predictive models. Our results show
the usefulness of data integration in finer understanding of gene expression in basal-like
breast cancers. In addition, a combination of data mining and feature selection techniques
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allow new genes related to basal-like breast cancers to be identified from many data
sources that may be otherwise difficult to detect. In particular, our results showed that the
most important genes that correlate with BLBC are ROPN1B and GABRP, SERPINB5,
FOXC1, KRT16 and KRT17. Our analysis provided new insights into the pathways
in the basal-like group of breast cancers which need to be further investigated in order to
develop BLBC specific treatments. The primary focus of different therapeutic approaches
for cancer treatment is cancer cells apoptosis. Nanomedicines may be the treatment of
choice for all the different types of cancer due to their excellent efficacy in penetration,
specific retention and killing of tumor cells. However, the success of nanomedicine is the
specific markers and signatures of the cancer cells which can be achieved by analyzing
gene datasets.
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